Awaiting development: Guidance and quality standards

Skip to filters Skip to results

Showing 1 to 25 of 325

Guidance and quality standards awaiting development
Title	Type
10395 - Aprocitentan for treating resistant hypertension TS ID 10395	Technology appraisal guidance
12 SQ-HDM SLIT for treating allergic rhinitis or rhinoconjunctivitis caused by house dust mites in children 5 to 11 years TSID 12049	Technology appraisal guidance
Abatacept for treating active idiopathic inflammatory myopathies TS ID 10095	Technology appraisal guidance
Abdominal aortic aneurysm	Quality standard
Abilify MyCite for treating bipolar disorder 1 or schizophrenia [ID3833]	Technology appraisal guidance
Acalabrutinib for treating relapsed or refractory mantle cell lymphoma [ID6389]	Technology appraisal guidance
Acalabrutinib with venetoclax and obinutuzumab for untreated chronic lymphocytic leukaemia [ID6156]	Technology appraisal guidance
Acalabrutinib with venetoclax with or without obinutuzumab for untreated chronic lymphocytic leukaemia ID6232	Technology appraisal guidance
Acne	Quality standard
Acoramidis for treating transthyretin-mediated amyloidosis cardiomyopathy [ID6354]	Technology appraisal guidance
Adalimumab for treating early Dupuytren's contracture TS ID 11870	Technology appraisal guidance
Adrenal dysfunction	Quality standard
Adults with lifelong or very severe hearing or visual impairment: health, well-being and social care	Quality standard
Advocacy services for adults with health and social care needs	Quality standard
Afamitresgene autoleucel for previously treated MAGE-A4 positive advanced synovial sarcoma or myxoid round cell liposarcoma [ID4064]	Technology appraisal guidance
Alpelisib for treating severe PIK3CA-related overgrowth spectrum in people 2 years and over [ID6252]	Technology appraisal guidance
Alpelisib with olaparib for treating BRCA wild-type platinum-refractory or -resistant ovarian, fallopian tube or primary peritoneal cancer after 1 to 3 previous treatments TS ID 11830	Technology appraisal guidance
Alpha-1 antitrypsin for treating high-risk acute graft-versus-host disease after a haematopoietic stem cell transplant in people 12 years and over TSID 12036	Technology appraisal guidance
Ambulatory pulmonary artery pressure monitoring devices	Diagnostics guidance
Andexanet alfa for reversing anticoagulation in people with intracranial haemorrhage (part review of TA697) [ID6335]	Technology appraisal guidance
Apadamtase alfa for preventing and treating congenital thrombotic thrombocytopenic purpura caused by ADAMTS-13 deficiency [ID6192]	Technology appraisal guidance
Apalutamide with radical prostatectomy for untreated high-risk, localised or locally advanced prostate cancer ID 6471	Technology appraisal guidance
Aquablation robotic therapy for lower urinary tract symptoms caused by benign prostatic hyperplasia	Medical technologies guidance
Atezolizumab as neoadjuvant (with chemotherapy) and adjuvant (as monotherapy) treatment for resectable non-small-cell lung cancer [ID3894]	Technology appraisal guidance
Avacincaptad pegol for treating geographic atrophy caused by age-related macular degeneration [ID6401]	Technology appraisal guidance

Results per page

10
25
50
All